6 ms·
FTC challenges 'junk' patents held by 10 drugmakers, incl Novo Nordisk's Ozempic
- hombre_fatal 3y agoThey clarify "junk" in the article (and linked article) to mean "improperly listed", but what does that actually mean for a drug like Ozempic?
- ChrisArchitect 3y agoOfficial release: https://www.ftc.gov/news-events/news/press-releases/2024/04/ftc-expands-patent-listing-challenges-targeting-more-300-junk-listings-diabetes-weight-loss-asthma https://www.ftc.gov/news-events/news/press-releases/2024/04/...
- andy_ppp 3y agoI’m so impressed with the FTC lately, here is an excellent interview Jon Stewart did with the FTC chair Lina Khan: https://youtu.be/oaDTiWaYfcM https://youtu.be/oaDTiWaYfcM I did joke I’m really surprised the vested interests selected someone competent who wants to hold these companies accountable to the public.
- germinalphrase 3y agoThere was a lot of chatter early in her tenure that she would be too young and inexperienced to be at all effective.
- cogman10 3y agoWhich is a little silly given her credentials. Her antitrust research has been groundbreaking. She's almost single-handedly revitalized that area of law.
- darth_avocado 3y agoSometimes, the old timers get too comfortable with the status quo and you need someone who is too young to challenge it.
- dylan604 3y agoLet's try that at the top of the chart instead of a couple steps down.
- roughly 3y agoThere's a lot of talk about "both sides being the same", but the FTC alone has been a night & day difference from previous administrations.
- knowaveragejoe 3y agoNobody suggesting that "both sides are the same" has a shred of intellectual honesty.
- wddkcs 3y agoDeclarative moral statements like this are so vacuous. Of course there are intellectually honest people who believe both parties are the same. They may be evaluating or prioritizing the evidence differently, but that doesn't make one side or the other 'dishonest'. Casually impuning the morality of an entire swath of people is rhetoric that drives division and strife, not progress. For example, yes Bidens FTC is a standout actor, but 'both sides' just voted to perpetuate overseas wars with more American tax dollars. In terms of the American war machine, it's 100% accurate to say both sides are the same.
- roughly 3y agoThen I suppose the appropriate way to phrase this would be "people suggesting both sides are the same need to qualify their statements."
- pessimizer 3y agoYou're making the assumption that they haven't, at length, until people got uncomfortable and wanted to leave.
- afavour 3y agoThe scenario you’re proposing sounds like one person lecturing another and not listening to any counter points… wanting to leave feels like a natural reaction.
- madeofpalk 3y agoChallenging things like this is a great first step, but they’ve got to actually win.
- jauntywundrkind 3y agoThe threat of litigation is often enough to change behaviors radically. For example, many companies that had taken advantage of putting devices into the Hatch-Waxman Orange Book being an unchecked unmonitored way to lay claim took their devices off once they saw the FTC starting to get interested. Adopting a narrow view of success is detrimental. Yes, it's hard as heck to figure out how to appreciate & be happy for "number of mergers never proposed because the FTChas actually started taking anti-trust seriously again". We will never have hard data. But for sure for sure for sure, companies are being more cautious, are thinking twice before trying to acquire their competitors or buying a company to land horizontal market control. Even losing is a detriment. The FTC had done nothing under Borkism. It was free reign. Even winning to the FTC isn't fun. It's expensive as heck, and there's a ton of discovery that happens & sheds light in a lot of dark dark places in your corporation. And other people see, hey, the FTC is out there, they're doing things, and maybe we won't get as lucky. Last, people act like, oh, the FTC lost, they must be incompetent & unable to build cases, but there's a ton of random chance & whim that goes into each case; replay a case in another courtroom or with different judges or juries and who knows what would have happenen.
- akira2501 3y agoGood. They patented inhalers for a second time. It's the exact same drug. The only thing that changed was the propellant. It went from R-12 to R-134a. Everyone who had to switch out R-12 from refrigeration to drug manufacturing switched to R-134a. There was absolutely _nothing_ novel about it. It was _criminal_ to allow them the second patent for just the propellant change. It took generic $5 inhalers off the market and replaced them with $95 inhalers. It was was one of the most corrupt swindles I've ever personally seen.
- Perepiska 3y agoIt could be interesting to see Ozempick prices for different countries: https://edition.cnn.com/2024/04/24/health/senate-ozempic-wegovy-price/index.html https://edition.cnn.com/2024/04/24/health/senate-ozempic-weg...
- RheingoldRiver 3y ago> It took generic $5 inhalers off the market and replaced them with $95 inhalers. OOTL, what is stopping companies from making generics of the older version & patients just not using the new version?
- chemeng 3y agoIt is illegal to use the previous propellant, so they can’t be manufactured anymore.
- chroma 3y agoWhere can I read more about this? If that’s true, it seems like a problem of over-regulation, not drug companies being exploitative.
- hed 3y agoR-12 is banned for manufacture by international treaty (which carries the force of law): https://en.wikipedia.org/wiki/Dichlorodifluoromethane https://en.wikipedia.org/wiki/Dichlorodifluoromethane
- microtherion 3y agoPresumably they have their grounds for the challenges, and the article says that each drug is covered by numerous patents, but I would be very surprised if Ozempic in particular lost ALL patent protection. Semaglutide itself seems to be a fairly revolutionary product, and reasonably different from Liraglutide (which I think predated it).
- siliconc0w 3y agoThe cost of healthcare should trend down as more and more drugs enter the public domain and generics become available. However this clearly isn't happening. It is also interesting when does the social benefit of a drug outweigh the benefit of creating an 'incentive' for drug companies. If GLP-1 drugs are worthy of the hype, we're basically talking about 20 years of unneeded suffering and trillions of dollars of avoidable damage to society all to give a drug company a limited monopoloy. At a certain point the US should just eminent domain the patent, give them some reasonable compensation, and make the drug broadly available to all Americans similar to COVID vaccines.
- chroma 3y agoSemaglutide was invented before 2008. Its patent expires in a few years. It takes a long time to get drugs through trials and get the FDA to approve drugs for new uses. Pharmaceutical companies spend billions on drugs that never make it through trials. If you don’t enforce their patents, companies won’t make new drugs.
- BizarroLand 3y agoOverseas the patent expires in 2026. I the USA, it will be "no later than" 2031.
- bodiekane 3y agoI wonder if a system like that could work. SpaceX and numerous other companies were able to draw in billions of dollars of funding for R&D to chase after US Government contracts that could only be won by proving massive technological feats (reusable rockets, etc). Hypothetically, it seems we could do something similar for drugs. Instead of "If you make a medicine that works, you get a monopoly to sell it for X years" it could just be "If you make a medicine that works, you get a check for $X, and then the drug is immediately generic".
- chroma 3y agoThe regulations are different. The FDA only gets in trouble if they approve a drug that turns out to be harmful, not if they fail to approve (or delay approving) a beneficial drug. On net, the FDA has caused far more harm than they’ve prevented. eg: Banning the importation of infant formula from the EU, or delaying the approval of new beta blockers by a decade.
- JumpCrisscross 3y agoFTC announcement: https://www.ftc.gov/news-events/news/press-releases/2024/04/ftc-expands-patent-listing-challenges-targeting-more-300-junk-listings-diabetes-weight-loss-asthma https://www.ftc.gov/news-events/news/press-releases/2024/04/... Note that this comes following “the Commission’s November challenges led to Kaleo Inc., Impax Labs, GlaxoSmithKline, and Glaxo Group delisting patents in response to the FTC’s warning letters” and subsequently “AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline all announc[ing] commitments to cap inhaler out-of-pocket costs at $35.” This process is precedented with delivering wins.
- superq 3y agoWhy are these junk patents, especially the Ozempic one? I want to believe! But I'm skeptical that it is a junk patent.
- modeless 3y agoNovo Nordisk stock didn't fall so either this was already known or people don't think it will have any effect.
- dpc_01234 3y agoThis article repeats the same thing 5 times or so. The headline is almost the whole article.
- deleted 3y ago[deleted]
- nojvek 3y agoFTC on a roll. I changed my opinion on Lina Khan. She’s actually getting shit done! I’m a fan.